Swiss National Bank Acquires 1,000 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Swiss National Bank grew its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 2.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 38,500 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. Swiss National Bank owned about 0.14% of Establishment Labs worth $1,774,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. R Squared Ltd bought a new stake in shares of Establishment Labs during the 4th quarter valued at approximately $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Establishment Labs in the third quarter valued at approximately $127,000. Handelsbanken Fonder AB grew its stake in shares of Establishment Labs by 32.3% during the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company’s stock worth $378,000 after buying an additional 2,000 shares during the last quarter. Verition Fund Management LLC increased its holdings in shares of Establishment Labs by 22.8% during the third quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock worth $407,000 after buying an additional 1,746 shares in the last quarter. Finally, Maven Securities LTD bought a new position in shares of Establishment Labs in the 3rd quarter valued at $433,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Down 0.5 %

Shares of NASDAQ:ESTA opened at $40.43 on Friday. The firm has a market cap of $1.17 billion, a P/E ratio of -15.67 and a beta of 0.95. Establishment Labs Holdings Inc. has a 12-month low of $28.16 and a 12-month high of $60.12. The business has a fifty day simple moving average of $36.36 and a 200 day simple moving average of $40.83. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm had revenue of $44.51 million during the quarter, compared to analyst estimates of $44.45 million. Analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and set a $52.00 price target on shares of Establishment Labs in a report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.40.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.